

Journal of Alzheimers Disease & Parkinsonism

2020 Market Analysis Open Access

2020 Market Analysis of 17th World Congress on Dementia & Alzheimer's Disease, October 19-20, 2020 | Vienna, Austria

Christopher Van Dyck

Professor of Psychiatry, Neurology and Neuroscience, United States, E-mail: christopher.vandyck@yale.edu

Dementia predominantly occurs in older people and, in view of the current demographic trend, has become a major issue for society and health policy. Currently around 130,000 people in Austria are suffering from some form of dementia and experts estimate that this number will double by 2050. Accounting for around 60-80% of cases, Alzheimer's disease is by far the most common form of dementia.

Dementia, including Alzheimer's disease, is one of the best overall general prosperity challenges facing our period. Around the globe, no under 44 million people are living with dementia this number is depended upon to two overlaps by 2030 and more than triple by 2050 to 115 million. A critical piece of the development will be in making countries like Western Europe and North America. Authoritatively 62% of people with dementia live in making countries. Today, more than 35 million people general directly live with the condition. This number is depended upon to twofold by 2030 and more than triple by 2050 to 115 million. No drugs available to direct or stop the cerebrum hurt caused by Alzheimer's disease, a couple of pharmaceuticals can quickly help upgrade the symptoms of dementia for a couple of individuals. In two decades, it is assessed that 1.4 million Canadians will have dementia, costing the \$300 economy almost billion consistently. Comprehensive, dementia cost \$600 billion a year.

The global dementia drugs market estimated to be valued at US\$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018–2026).

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered with <u>vascular dementia</u> during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 per cent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated in increase to 63 per cent in 2030 and 71 per cent in 2050. The values are

expected to double by 2030 and triple by 2050 to 115 million.

Glance at Market of Dementia:

The total estimated worldwide cost of dementia is US\$ 818 billion in 2015, which represents 1.09% of global GDP. By 2018, the global cost of dementia will rise above a US\$ trillion.


This figure includes costs attributed to informal care (unpaid care provided by family and others), direct costs of social care (provided by community care professionals, and in residential home settings) and the direct costs of medical care (the costs of treating dementia and other conditions in primary and secondary care).

Direct medical care costs account for roughly 20% of global dementia costs, while direct social sector costs and informal care costs each account for roughly 40%. The relative contribution of informal care is greatest in the African regions and lowest in North America, Western Europe and some South American regions, while the reverse is true for social sector costs.

Multi-infarct Dementia (MID) is one of the common causes of memory loss among elderly people as a result of reduced blood flow to parts of the brain. Globally, Development of efficient and advance technology, Rise in the demand for novel diagnostic Product. Rising demand for point of care devices segment and Growing demand for Multi-Infarct Dementias demand in end-use industries are the prime growth drivers of global Near Infrared Imaging market. In addition, increase in adoption of Multi-Infarct Dementia for newer applications, will create new opportunities for global near multi infarct dementia market. However, higher cost of the research and development, lack of awareness and Sustainability in market are the key restraints for global Near Infrared Imaging market.

This report identifies the <u>Global Multi-Infarct Dementia</u> market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Multi-Infarct Dementia market.

Multi-Infarct Dementia Market, Value 2016-2021 (\$Million)




Source: IndustryARCAnalysis, Expert Insights

Geographically North America dominated global Multi-Infarct Dementia market, and Europe is projected to have fastest growth, while it is the most common type of dementia in Asia and other parts of the world. For instance, it accounts for more than 50% of dementia cases in Japan. The prevalence of Multi-Infarct Dementia (MID) is expected to rise drastically in the near future given the exponential rise in geriatric population of the world. Therefore, the global Multi-Infarct Dementia (MID) market is expected to grow rapidly in the developed nations such as the U.S., Canada, Germany, France, and Japan where there is enormous rise in the elderly people.

Treatment for Syndromes of Dementia and Movement Disorders Market Overview:

Global Treatment for Syndromes of Dementia and Movement Disorders Market is estimated to reach \$28.6 Billion by 2024; growing at a CAGR of 8.9% from 2016 to 2024. Dementia is basically an assortment of symptoms triggered by disorders affecting the brain. Dementia majorly affects thinking capability, and ability to perform day-to-day tasks. Dementia and movement disorders are caused due to brain damages instigated by diseases or a series of strokes. Persons above the age of 65 years are more prone to be affected by these disorders. According to World Alzheimer Report 2015,

46 million people are suffering from dementia and the number is expected to rise to 131.5 million by 2050.



Rapidly increasing geriatric population, growing consumer awareness, and availability of various healthcare services such as psychological therapies, and homecare services are the key factors supporting the growth of the market. However, lack of proper management of these disorders and long approval time for drugs and devices may hamper the growth of the market.

The Key Takeaways from the Report:

- The report will provide a detailed analysis of Global Treatment for Syndromes of Dementia and Movement Disorders Market with respect to major segments such as type, and geography
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and Compound Annual Growth Rate (CAGR) between 2016 and 2024
- Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
- An exhaustive regional analysis of Global Treatment for Syndromes of Dementia and Movement Disorders Market from 2015 to 2024 has been included in the report
- Profile of the key players in the Global Treatment for Syndromes of Dementia and Movement Disorders Market will be provided, which include key financials, product & services, new developments and business strategies.